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Background: The nigrosome-1 region of the substantia nigra (SN) undergoes the great-
est and earliest dopaminergic neuron loss in Parkinson’s disease (PD). As T2-weighted 
magnetic resonance imaging (MRI) scans are often collected with routine clinical MRI 
protocols, this investigation aims to determine whether T2-imaging changes in the nigro-
some-1 are related to clinical measures of PD and to assess their potential as a more 
clinically accessible biomarker for PD.
Methods: Voxel intensity ratios were calculated for T2-weighted MRI scans from 47 
subjects from the Parkinson’s Progression Markers Initiative database. Three approaches 
were used to delineate the SN and nigrosome-1: (1) manual segmentation, (2) auto-
mated segmentation, and (3) area voxel-based morphometry. Voxel intensity ratios were 
calculated from voxel intensity values taken from the nigrosome-1 and two areas of the 
remaining SN. Linear regression analyses were conducted relating voxel intensity ratios 
with the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS) sub-scores for each subject.
results: For manual segmentation, linear regression tests consistently identified the 
voxel intensity ratio derived from the dorsolateral SN and nigrosome-1 (IR2) as predictive 
of nBehav (p = 0.0377) and nExp (p = 0.03856). For automated segmentation, linear 
regression tests identified IR2 as predictive of Subscore IA (nBehav) (p =  0.01134), 
Subscore IB (nExp) (p = 0.00336), Score II (mExp) (p = 0.02125), and Score III (mSign) 
(p = 0.008139). For the voxel-based morphometric approach, univariate simple linear 
regression analysis identified IR2 as yielding significant results for nBehav (p = 0.003102), 
mExp (p = 0.0172), and mSign (p = 0.00393).
conclusion: Neuroimaging biomarkers may be used as a proxy of changes in the 
nigrosome-1, measured by MDS-UPDRS scores as an indicator of the severity of PD. 
The voxel intensity ratio derived from the dorsolateral SN and nigrosome-1 was con-
sistently predictive of non-motor complex behaviors in all three analyses and predictive 
of non-motor experiences of daily living, motor experiences of daily living, and motor 
signs of PD in two of the three analyses. These results suggest that T2 changes in the 
nigrosome-1 may relate to certain clinical measures of PD. T2 changes in the nigro-
some-1 may be considered when developing a more accessible clinical diagnostic tool 
for patients with suspected PD.
Keywords: movement disorders, Parkinson’s disease, Mri, nigrosome-1
TaBle 1 | Demographic information.
Parkinson’s disease  
subjects
controls p-value
Age, SD (years) 62, 9 60, 12 0.59
Gender (% male) 53.3 58.8 0.809
Caucasian (%) 100 94.1 0.3605
Right-handed (%) 96.7 100 0.0806
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inTrODUcTiOn
There has been recent interest in determining a reliable in vivo 
biomarker for Parkinson’s disease (PD), a neurodegenerative 
disorder characterized by motor and non-motor symptoms. The 
hallmark symptoms of PD, such as resting tremors, bradykinesia, 
rigidity, and postural instability, are related to dopamine (DA) 
deficiency (1, 2). An ideal imaging marker is expected to reflect 
progressive loss of dopaminergic neurons. For such purpose, the 
nigrosomes within the substantia nigra (SN) region are of particu-
lar interest, because they have the highest density of dopaminergic 
neurons (3). The largest nigrosome is the nigrosome-1, and it is 
lens-shaped and situated along the rostral/caudal axis of the SN in 
its dorsal part, at the caudal and intermediate levels (4, 5).
Recent studies noted that high-resolution 7 and 3  T T2*-
susceptibility-weighted (SWI) magnetic resonance imaging 
(MRI) can directly visualize the nigrosome-1 in healthy controls 
due to the SWI sensitivity for iron (5, 6). However, T2-weighted 
imaging is more commonly used in routine MRI protocols than 
SWI. T2-weighted imaging, being sensitive to local magnetic field 
inhomogeneities, is also modified in the presence of iron, with 
previous studies suggesting its potential to serve as a non-invasive 
estimate of iron content in the brain (7–9). Previous studies have 
implicated that changes in iron levels in the SN of the PD-affected 
brain may have an influence on the selective and progressive 
dopaminergic neurodegeneration seen in PD (10, 11). As pro-
gressive dopaminergic neurodegeneration is characteristic of 
PD, T2-weighted images may be able to detect the change in iron 
content in the nigrosome-1 of PD subjects. Using T2-weighted 
images from both PD subjects and healthy controls, we related 
voxel intensity ratios derived from the nigrosome-1 and two 
other regions of the SN with clinical measures of PD to determine 
whether the nigrosome-1 can serve as a more readily accessible, 
potential biomarker for PD, thereby serving as an indicator of 
disease progression.
MaTerials anD MeThODs
Dataset and study Population
Data used in the preparation of this article were obtained from 
the Parkinson’s Progression Markers Initiative (PPMI) database 
(www.ppmi-info.org/data). The PPMI is a multi-center trial 
involving 33 centers in North America, Europe, Israel, and 
Australia for 3–5  years with a primary objective to identify 
clinical, imaging, and biologic markers of PD progression for 
use in clinical trials of disease-modifying therapies. The sample 
consisted of a total of 47 subjects, with 17 healthy controls and 
30 patients with PD. Mean age (±SD) was 61.1 (±10.2) years. 
There were 21 females and 26 males. Subjects’ disease status 
was determined according to the PPMI selection criteria for PD 
patients (12). According to the main eligibility criteria of the 
PPMI protocol, all PD subjects were Hoehn and Yahr stage I or II 
at baseline. Patients must have had at least two of the following: 
resting tremor, bradykinesia, rigidity (must have either resting 
tremor or bradykinesia) or either asymmetric resting tremor or 
asymmetric bradykinesia. All subjects had Geriatric Depression 
Scale scores within normal ranges. In addition, exclusion criteria 
included subjects who received any of the following drugs that 
may interfere with DA transporter SPECT imaging: neuroleptics, 
metoclopramide, alpha methyldopa, methylphenidate, reserpine, 
or amphetamine derivative, within 6  months of screening. 
Current treatment with anticoagulants (e.g., coumadin, heparin) 
that might preclude safe completion of the lumbar puncture was 
another exclusion criteria. Additional demographic data about 
the subjects can be found in Table 1.
Initially, 265 potential subjects were screened and rated for 
the clarity of the SN and nigrosome-1. A strict quality-control 
process was imposed during subject selection to improve the 
quality of the manual segmentation analysis, the next step of 
the analysis. The quality-control process considered both signal-
to-noise ratios and dynamic range in contrast and was done 
without knowledge of the cohort to which each subject belonged. 
In addition, the selection criteria were as follows: (1) axial scan 
acquisition, (2) 3-T field strength, and (3) the visualization of the 
nigrosome-1 as a region of signal hyperintensity in the posterior 
third of the SN surrounded by low signal intensity anterior and 
laterally (pars compacta SN) and medially by low signal from the 
medial lemniscus. Because this study involved manual segmenta-
tion, to avoid inaccuracy, two separate, blinded raters determined 
that the scans of 50 subjects among the 265 had a sufficiently 
visible nigrosome-1 to proceed with the analysis. The two raters 
were blinded as to whether the subjects were of the PD or control 
cohort. Therefore, only 50 subjects were deemed appropriate 
for the subsequent segmentation analyses based upon the strict 
quality-control process and selection criteria imposed upon the 
images, as a measure to improve the quality of the future analyses 
and reduce the likelihood of inaccuracy during manual segmen-
tation. Three subjects scanned on the Discovery MR750 machine 
model were then removed from further analyses to reduce pos-
sible heterogeneity of scanner hardware.
image acquisition and scanning
Subjects were scanned at 3 T using T2-weighted, axial acquisi-
tion sequences with a scan time of 5 min and 8 s. MRI data was 
acquired on either a Siemens TrioTim system or GE Medical 
Systems SignaHDxt system. The resolution ranged from 
0.49 mm × 0.49 mm × 2.0 mm to 0.94 mm × 0.94 mm × 3.0 mm, 
TR (repetition time) ranged from 3000 to 4500 ms, TE (echo time) 
ranged from 11 to 105.98 ms, flip angle was either 90° or 150°, and 
matrix size ranged from 204 × 256 × 48 voxels to 512 × 512 × 84 
voxels.
Behavioral Measures
Behavioral measures were compiled using the PPMI database. 
Movement Disorder Society-Unified Parkinson’s Disease Rating 
TaBle 2 | The six different tests that composed subscore ia (nBehav) 
and the seven different tests that composed subscore iB (nexp).
Part ia: complex behaviors (nBehav) Part iB: patient experiences 
(nexp)
Cognitive impairment Sleep problems
Hallucinations and psychosis Daytime sleepiness
Depressed mood Pain and other sensations
Anxious mood Urinary problems
Apathy Constipation problems
Features of dopamine dysregulation syndrome Light headedness on standing
– Fatigue
FigUre 1 | Distribution of clinical MDs-UPDrs data.
3
Fu et al. T2 Nigrosome-1 Relates to Parkinson’s Disease
Frontiers in Neurology | www.frontiersin.org October 2016 | Volume 7 | Article 174
Scale (MDS-UPDRS) subscores were calculated and compiled 
for each subject. Part I (non-motor) scores measured non-motor 
experiences of daily living consisting of Subscore IA (nBehav), 
which focused on complex behaviors, and IB (nExp), which 
focused on the patient’s experiences regarding non-motor experi-
ences of daily living; Part II (mExp) measured motor experiences 
of daily living; and Part III (mSign) measured motor signs of PD 
(13). The tests that composed Subscores IA and IB can be found 
in Table 2.
The results of the MDS-UPDRS clinical measures demon-
strated a median score of 7 and range of 0–19 for non-motor 
behaviors and experiences, a median score of 2 and range of 0–17 
for motor experiences, and a median score of 13 and range of 
0–36 for motor signs. The distribution of the clinical data can be 
found in histogram format in Figure 1.
image Processing
Three approaches were used to locate the SN region and nigro-
some-1 region: manual segmentation, automated segmenta-
tion, and area voxel-based morphometry. Details of the three 
approaches are as follows.
Manual Segmentation
The manual segmentation component involved the manual seg-
mentation of regions of interest (ROIs) following a standardized 
protocol. The SN and nigrosome-1 were manually segmented by 
two separate experts who had followed the protocol below when 
conducting the segmentation. The most inferior axial slice where 
the red nucleus was still visible was used for the segmentation 
of the SN and nigrosome-1, and this was done uniformly for all 
subjects. The SN was located in the mesencephalon, posterior 
(dorsal) to the crus cerebri, anterior (ventral) to the midbrain 
tegmentum, and inferolaterally to the red nucleus (14). As previ-
ously described, it lies at an oblique angle with its superior bound-
ary most lateral. It is typically divided into two functionally and 
anatomically distinct parts: the inferior (caudal) and posterior 
(dorsal) SN pars compacta (SNc), which has melanin-containing 
neurons, and the superior (rostral) and anterior (ventral) SNr 
(15). Based on previous MR studies (15), the SN pars reticulata 
was identified as the region of signal hypointensity on T2 in the 
midbrain. The nigrosome-1 was identified as the signal hyperin-
tensity in the posterior third of the SN and was surrounded by 
low signal intensity anteriorly and laterally by relatively low signal 
from the cerebral peduncles and medially by low signal from the 
red nucleus and SN pars reticulata (15) (Figure 2).
Automated Segmentation of Substantia Nigra
All normal controls’ T2-weighted images were coregistered to 
build a template structural image, which then served as the com-
mon space for automated segmentation. The spatial correspond-
ences, established between subject images and the template image 
with non-linear registration, were used to propagate manual seg-
mentation results. Manual segmentation of three subject images 
selected at random out of the total sample was mapped to the 
template space and averaged. This averaged segmentation in the 
FigUre 2 | (a) Schematic diagram of ROIs and (B) ROIs as seen on patient MRI scan.
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template space was propagated to all subject images, including the 
three original input subject images. Segmentations of the three 
subjects’ images were therefore regenerated with the automated 
segmentation protocol.
Non-linear registration was performed with Advanced 
Normalization Tools (ANTs) registration (16). The ANTs regis-
tration tool first performs linear alignment of images to correct 
orientation mismatch, then performs non-linear deformation to 
register images. In our experience, ANTs is very robust in han-
dling orientation mismatch, as long as the images are not turned 
beyond 90 degrees.
As a preprocessing step of spatial normalization, all T2-weighted 
images were skull-stripped with the FSL5 Brain Extraction Tool 
(BET) version 5.0.2 (17). This automated segmentation pipeline, 
as illustrated in Figure 3, output segmentations of the SN (exclud-
ing the nigrosome-1) of the remaining T2-weighted images (18, 
19). The nigrosome-1 was then manually determined based on 
the gap left within the SN segmentation.
The pipeline workflow includes two complementary compo-
nents, divided by the red dashed line in Figure 3. The left side 
of the pipeline constructs the SN in the atlas image. Module R1 
uses subjects’ structural images from Input B and non-linearly 
registers them to the structural atlas specified by Input A. 
Module W1 then takes the non-linear transformations output 
by Module R1 and applies them to warp the manually segmented 
SN binary masks (Input A) into the atlas space. These spatially 
normalized masks are averaged to produce Output E, which 
is the averaged SN in the atlas space. Input A and B are both 
skull-stripped images. The right side of the pipeline, as illustrated 
in Figure  3, propagates the SN region from the atlas space to 
subjects’ native spaces. Input D includes the structural images 
of the 47 subjects. After correction for field inhomogeneity and 
skull stripping, they are registered to the atlas space by Module 
R2. Module R2 outputs a two-way transformation: the forward 
warp from subject spaces to the atlas space and the inverse warp 
from the atlas space to subject spaces. Module W2 uses the 
inverse transformations and applies them to propagate the SN 
segmentation from the atlas to each of the subjects’ spaces as 
Output F, which yields the results of the automatic segmentation. 
Module W3 takes the forward transformations and applies them 
to warp subject images to the atlas space for registration quality 
control. Please note that Pipe G feeds the segmentation in the 
atlas into Module W2, connecting the left part and the right 
part of the workflow. The atlas input C, shared by both the 
left and the right parts, is constructed from structural images 
of all normal control subjects, with ANTs, in a way similar to 
that for the construction of the Montreal Neurological Institute 
(MNI) atlas.
In Modules R1 and R2, the number of non-linear registration 
iterations was set to 50 × 50 × 50, while linear iterations were set 
to 1000 × 1000 × 1000. The energy function used was “mutual 
information,” and the transformation model used was “SyN.”
Area Voxel-Based Morphometric Approach
The area voxel-based morphometric (aVBM) approach utilized 
an automated segmentation process as well. The same template 
structural image created for the automated segmentation process 
was used for the aVBM approach. This aVBM approach used 
circular ROIs as opposed to a segmentation approach that 
yielded ROIs based on the anatomy of the SN and nigrosome-1. 
ROIs were drawn for four subjects selected randomly from the 
total sample in three regions of the SN: (1) nigrosome-1, (2) 
ventromedial region of the SN, and (3) outer “swallow tail” of 
the SN, a region dorsolaterally adjacent to the nigrosome-1. The 
spatial correspondences established between subject images 
and the template image with non-linear image registration were 
used to segment these 3 ROIs on all 47 subjects, as was done in 
the automated segmentation protocol using the same pipeline 
(Figure 3). The voxel intensity ratios were then calculated from 
these ROIs.
Voxel intensity analyses
Two voxel intensity ratios were calculated (IR1 and IR2) using 
the most inferior axial slice where the red nucleus is still visible. 
To reduce intensity variability of a single voxel, five voxels were 
randomly sampled from each ROI. The region spanned by the 
FigUre 3 | Pipeline workflow illustrating the automated segmentation process.
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five voxels covers 60–100% of the ROI. Therefore, the mean of 
the five voxels adequately represented the intensity of the ROI. Let 
rNigro1 and lNigro1 denote the set of voxel intensities sampled 
from the nigrosome-1 on the right and left sides, respectively, 
rVentral and lVentral denote those from the ventral–medial 
portion of the SN on the right and left sides, respectively, and 
rSwallow and lSwallow denote those from the outer swallow tail 
on the right side and left side, respectively (Figure 2). IR1 and IR2 
were calculated as follows:
 
IR
mean rNigro
mean rVentral
mean lNigro
mean lVentral1
1 1
=
+( )( )
( )
( )
( )
( )
( )
(
2
2
1 1
and
IR
mean rNigro
mean rSwallow
mean lNigro
mean lS=
+ wallow)
2  
Because IR1 and IR2 are ratios of image intensities, the scan-
ners used for image acquisition should have a limited impact on 
these indices.
statistical analysis
Multivariate Multiple Regression Analysis
We employed descriptive statistics, multivariate analysis of vari-
ance, and linear regression to examine the relationships between 
predictive imaging biomarkers and clinical PD measures (20, 
21). In our linear regression models, the explanatory variables 
X include the intensity ratios, IR1 and IR2, derived from the 
nigrosome-1 in the SN. The responding variables (Y) include 
four MDS-UPDRS measures: nBehav, nExp, mExp, and mSign, 
as defined below:
 • MDS-UPDRS:
 ◦ Part I: non-motor experiences of daily living;
 ▪ Subscore IA: complex behaviors (nBehav);
 ▪  Subscore IB: non-motor experiences of daily living – 
patient experiences (nExp).
 ◦ Part II: motor experiences of daily living (mExp);
 ◦ Part III: motor signs of PD (mSign).
FigUre 4 | slice thickness and voxel intensity ratios (ir1).
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We used power analysis (21, 22) to estimate the statistical power 
of our multivariate linear model. Using default false-positive rate 
of a =  0.05, the available group sample sizes (controls: 17 and 
patients: 30), effect-size of 0.70, and assuming relative independ-
ence of the predictors (unitary variance inflation factors) and 
equal variability in each cohort, we estimated that the power to 
detect a grouping effect is 0.95.
resUlTs
slice Thickness
To address the concern that the different scanner types and slice 
thicknesses may potentially affect the results of the voxel intensity 
ratios, scatterplots were created to demonstrate that the differ-
ences in scan acquisition and slice thickness yielded a similar 
distribution of data (Figures 4 and 5).
linear Modeling
Manual Segmentation
The results of fitting the multivariate multiple regression model 
for the manual segmentation analyses indicate that the predictor 
vector of intensity ratios, X = {IR1, IR2}, is border-line significant 
in explaining the observed response (clinical PD measurements) 
Y, p = 0.04956. Fitting a linear regression model on the individual 
responses (Y ~ IR1 + IR2) showed that linear regression tests con-
sistently identified the IR2 as predictive of nBehav (p = 0.0377) 
and nExp (p = 0.03856).
Automated Segmentation
For automated segmentation, multivariate multiple linear 
regression analysis to predict the response vector Y = {nBehav, 
nExp, mExp, mSign} from the imaging biomarkers X =  {IR1, 
IR2} did not provide significant evidence of association 
(MANOVA Wilks test, p = 0.09564). However, linear regression 
tests consistently identified the IR2 as predictive of nBehav 
(p  =  0.01), nExp (p  =  0.00336), mExp (p  =  0.02125), and 
mSign (p =  0.008139).
Area Voxel-Based Morphometric Analysis
Multivariate multiple linear regression analysis to predict the 
response vector Y =  {nBehav, nExp, mExp, mSign} from the 
imaging biomarkers, X = {IR1, IR2} provided significant results 
for nBehav (p =  0.008991), mExp (p =  0.04869), and mSign 
(p =  0.01489). For univariate simple linear regression analysis, 
IR2 yielded significant results for nBehav (p = 0.003102), mExp 
(p = 0.0172), and mSign (p = 0.00393).
DiscUssiOn
Previous research on the nigrosome-1 has suggested that visuali-
zation of this high signal intensity wedge may have the potential 
to serve as a simple, sensitive, and specific diagnostic tool for 
PD, using either 7 or 3 T T2*-weighted SWI sequences (5, 6, 23). 
These investigations used blinded radiologists or neurologists to 
determine the diagnostic accuracy of this type of visual radio-
logic assessment, predicting whether subjects were diagnosed 
with PD or were healthy controls. Nevertheless, T2-weighted 
images are often obtained in routine clinical MRI protocols and 
are thereby more readily accessible. In contrast to these studies, 
we therefore aimed to determine whether the nigrosome-1 could 
serve as a more readily accessible, potential biomarker for PD 
using T2-weighted images, in that changes in the nigrosome-1 
correspond with signs of PD progression as assessed by the 
MDS-UPDRS.
The ability to visualize the nigrosome-1 on MRI has been 
associated with the T2*-weighted SWI sequence’s sensitivity for 
iron (24). T2-weighted imaging, while not as sensitive to iron 
as SWI sequences, is also sensitive to local magnetic field inho-
mogeneities and modified in the presence of iron, with previous 
studies suggesting its potential to serve as a non-invasive estimate 
of iron content in the brain (7–9). Whereas the majority of studies 
investigating the nigrosome-1 and its degeneration in PD have 
focused on its direct visualization with 7 or 3  T T2*-weighted 
SWI sequences, we demonstrated positive findings even when 
using T2-weighted images. Because sensitivity of T2 is less than 
SWI, the positive findings here were more conservatively derived 
than those of SWI. Recent research has focused on improved 
imaging of the SN, including the use of new MRI techniques, 
such as “neuromelanin-sensitive MRI” (NM-MRI) and quan-
titative susceptibility mapping (QSM), which have been found 
to provide notable contrast between the SN and surrounding 
brain tissues with potential applications as biomarker of PD (25, 
26). While these innovative neuroimaging techniques continue 
to improve the resolution of SN imaging, standard structural 
T2- and T1-weighted MRIs are often normally acquired during 
FigUre 5 | slice thickness and voxel intensity ratios (ir2).
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early PD. T2-weighted imaging may therefore be more prevalent 
and readily available than T2*-weighted SWI sequences (27). The 
results of this investigation suggest its potential applicability to 
the development of a more accessible neuroimaging diagnostic 
tool for PD patients, as T2-weighted MRI images are routinely 
collected as a part of standard imaging protocol in comparison 
to SWI or T2* images.
In this study, we selected subjects with neuroimaging data 
providing sufficient detail for automated extraction of the nigro-
some-1. This protocol avoids biases and inconsistencies of manual 
segmentation that may otherwise influence the first component 
of this study. To enable the comparison of the automatic segmen-
tation results and their manual segmentation counterparts, we 
used a paired design with the same subjects processed via both 
approaches. Previous studies have used automatic segmentation 
techniques in morphometric studies relating to neurological 
diseases (28, 29), while other studies employed a combination of 
manual and automated segmentation techniques, similar to this 
investigation (30, 31). The results of the automatic segmentation 
approach in this analysis demonstrated a stronger association 
between the voxel intensity ratios and clinical measures of PD 
than the manual segmentation approach. Computer-based 
8Fu et al. T2 Nigrosome-1 Relates to Parkinson’s Disease
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automatic segmentation, more quantitative than human manual 
segmentation, may be able to detect the nigrosome-1 even when 
it is difficult by visual inspection. Therefore, the addition of an 
automated segmentation approach to the manual segmentation 
approach alone in this analysis likely reduced inter- and intra-
rater segmentation quality incoherence. We will further compare 
automatic segmentation and manual segmentation of nigro-
some-1 in future studies.
Further, by calculating voxel intensity ratios instead of using 
absolute voxel intensity values, we accounted for changes in 
iron levels throughout the basal ganglia that may occur with 
aging (32). Nevertheless, while our hypothesis is originally 
based upon previous literature that suggests that changes in 
the nigrosome-1 in PD patients may be reflective of changes 
in iron levels in the basal ganglia in PD, the manner by which 
T2-weighted MRI changes in the nigrosome-1 relate to clinical 
measures of PD remains unclear. While T2-weighted MRI’s 
susceptibility to iron inhomogeneities may play a role, other 
factors may also contribute, which merit further elucidation 
by future studies.
The results of our statistical analyses revealed that IR2, 
derived from the nigrosome-1 and the area immediately dorso-
lateral to it, seemed to be more impactful and better correlated 
with MDS-UPDRS scores than IR1, derived from the nigro-
some-1 and a ventromedial area of the SN. Similarly, the results 
of the linear regression analysis for the automated segmenta-
tion component of the analysis demonstrated that IR2 was a 
significant predictor of the MDS-UPDRS scores but IR1 was 
not. This finding may be related to the pattern of dopaminergic 
loss in the SN in PD patients, as dopaminergic neuronal loss is 
most pronounced in the caudal and ventrolateral tier, with the 
dorsal tier being the most preserved (3, 33, 34). Dopaminergic 
neuron loss is highest in the nigrosomes, with maximal loss 
(98%) in nigrosome-1 (3), and then the loss progresses to other 
nigrosomes and the remaining matrix along rostral, medial, and 
dorsal axes. In this case, a ratio derived from the nigrosome-1, 
experiencing the highest levels of dopaminergic loss, and the 
dorsolateral SN, experiencing minimal loss, has the greatest 
likelihood of corresponding with PD progression as captured 
by MDS-UPDRS scores. In contrast, a ratio derived from the 
nigrosome-1 and a ventromedial area of SN, which may also 
be experiencing certain levels of dopaminergic loss, would not 
correspond as well.
One might expect the imaging biomarkers to show the strong-
est correlation with Part III scores, which is the motor examina-
tion of the MDS-UPDRS conducted by a physician. However, 
partial correlations between IR2 and all score components of 
the MDS-UPDRS either in the manual segmentation analysis 
or in the automated segmentation analysis were significant. This 
suggests that voxel intensity ratios have the potential to not only 
relate to motor signs of PD, as assessed by a third-party examiner 
that is not the caregiver or patient, but also relate to self-reported 
patient questionnaires.
While changes in PD patients may be associated with changes 
in iron content in the nigrosome, other possible mechanisms 
involved include neuronal cell loss, changes in neuromelanin, 
a change in iron oxidation state, or a combination of these 
effects (5). While this study is based upon T2 sequence sensitiv-
ity for iron, it does not elucidate the exact mechanism of the 
changes in the nigrosome-1 that correspond with PD progres-
sion. Additional research is needed to further elucidate these 
mechanisms.
The results of this investigation support previous research, 
suggesting that the nigrosome-1 as a region of signal hyperin-
tensity may relate to the symptoms seen in PD. More specifi-
cally, this study suggests that there is an association between 
T2-weighted MRI changes in the nigrosome-1 and clinical 
measures of PD as assessed by the MDS-UPDRS. There has 
also been recent interest in determining whether the nigro-
some-1 is capable of differentiating different neurodegenerative 
Parkinsonism presentations, including PD, multiple system 
atrophy (MSA), and progressive supranuclear palsy (PSP) 
(23). Additional studies can investigate whether changes in the 
nigrosome-1 correlate with clinical manifestations of MSA or 
PSP in addition to PD.
We demonstrate support for the a  priori hypothesis that 
voxel intensity ratios derived from T2-weighted imaging 
may serve as predictors of MDS-UPDRS scores based on the 
results of our linear regression analyses. The voxel intensity 
ratio derived from the dorsolateral SN and nigrosome-1 was 
consistently predictive of non-motor complex behaviors in 
all three analyses and predictive of non-motor experiences of 
daily living, motor experiences of daily living, and motor signs 
of PD in two of the three analyses. T2-weighted images are 
often obtained more readily in routine clinical MRI protocols 
than other sequences. Our results suggest that T2 changes in 
the nigrosome-1 may be considered when developing a more 
accessible clinical diagnostic tool for patients with suspected 
PD in the future.
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